EGFR-mutated NSCLC treatment shifts toward combination therapies

Treatment paradigms for first-line epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) are shifting toward intensified regimens. Medical experts note a transition from single-agent tyrosine kinase inhibitor (TKI) therapy to combination options that offer improved overall survival benefits.

Clinical findings indicate that combining the novel agent tegavivint with osimertinib shows early therapeutic activity in treatment-naive patients. This combination approach aims to target complex resistance pathways and molecular survival routes that often limit the effectiveness of standard monotherapies. While single-agent TKI therapy remains an option for specific cases, such as older patients with comorbidities, intensified regimens are increasingly utilized to prevent rapid disease progression.